%0 Journal Article
%T PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?
%A Addeo, Alfredo
%A Banna, Giuseppe Luigi
%J Translational Lung Cancer Research
%D 2018
%B 2018
%9 
%! PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?
%K 
%X Immune checkpoint inhibitors (ICPIs) targeting the programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) axis have dramatically expanded the therapeutic armamentarium for non-small cell lung cancer (NSCLC) and are now standard treatments for patients with advanced disease (1).
%U https://tlcr.amegroups.org/article/view/23046
%P S283-S286
%@ 2226-4477